Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745568 | 1.00 | MPI (0.40) | MPIAKR1B1TSHRTDP1ALDH1A1 | |
| Phosphoric Acid SCHEMBL5792557 | 0.91 | MPI (0.48) | MPI | |
| SCHEMBL16600269 | 0.85 | MPI (0.33) | MPI | |
| SCHEMBL17984946 | 0.82 | MPI (0.39) | MPIAKR1B1 | |
| SCHEMBL17984945 | 0.77 | MPI (0.39) | MPIAKR1B1TSHRTDP1ALDH1A1 | |
| SCHEMBL6436950 | 0.76 | TSHR (0.33) | TSHRTDP1ALDH1A1 | |
| SCHEMBL16600605 | 0.75 | MPI (0.38) | MPIALDH1A1 | |
| SCHEMBL9842949 | 0.74 | TSHR (0.32) | TSHRTDP1ALDH1A1 | |
| SCHEMBL29876881 | 0.73 | TSHR (0.47) | TSHRTDP1ALDH1A1 | |
| SCHEMBL16600199 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351847-B2 | Methods for the improved formation of acarbose | UNIVERSITÄT BIELEFELD (DE) | 2025-07-08 | — | — | US | disclosed |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| US-20230227879-A1 | METHODS FOR THE IMPROVED FORMATION OF ACARBOSE | UNIVERSITÄT BIELEFELD (DE) | 2023-07-20 | — | — | US | disclosed |
| EP-4045520-A1 | METHODS FOR THE IMPROVED FORMATION OF ACARBOSE | Bayer Aktiengesellschaft (DE) | 2022-08-24 | — | — | EP | disclosed |
| CN-114555811-A | Method for improving acarbose formation | 拜耳公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| US-20180344875-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2018-12-06 | — | — | US | disclosed |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2016-08-18 | — | — | US | disclosed |
| EP-3049473-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015042711-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE, INC. (CA) | 2015-04-02 | — | — | WO | disclosed |
| US-20040161839-A1 | Method to alter sugar moieties | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2004-08-19 | — | — | US | disclosed |
| EP-1325134-A2 | METHOD TO ALTER SUGAR MOIETIES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030073824-A1 | DNA encoding methymycin and pikromycin | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2003-04-17 | — | — | US | disclosed |
| WO-2002029035-A2 | METHOD TO ALTER SUGAR MOIETIES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-1090125-A2 | DNA ENCODING METHYMYCIN AND PIKROMYCIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000620-A2 | DNA ENCODING METHYMYCIN AND PIKROMYCIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180344875-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | MPI 2113/4885AKR1B1 3046/4885TSHR 4331/4885 |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | MPI 2113/4885AKR1B1 3046/4885TSHR 4331/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | MPI 2113/4885AKR1B1 3046/4885TSHR 4331/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | MPI 2113/4885AKR1B1 3046/4885TSHR 4331/4885 |
| US-20160235863-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | MPI 2113/4885AKR1B1 3046/4885TSHR 4331/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | MPI 2113/4885AKR1B1 3046/4885TSHR 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.